Pure Global
NCT06267183

A Clinical Study to Evaluate Safety, Tolerability and Pharmacokinetics of SV001 in Chinese Healthy Adult Volunteers.

A Phase I, Single-center, Randomized, Double-blind, Single-dose, Dose-ascending, Placebo-controlled Clinical Study to Evaluate Safety, Tolerability and Pharmacokinetics of SV001 in Chinese Healthy Adult Volunteers.
Shanghai Synvida Biotechnology Co.,Ltd.·Phase 1·ClinicalTrials.gov·drugRecruiting
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Idiopathic Pulmonary Fibrosis
Drug/Device/Intervention
SV001
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
Shanghai Synvida Biotechnology Co.,Ltd.
Location
Shanghai, China
Timeline & enrollment
Phase
Phase 1
Start date
Jan 12, 2024
End date
Mar 30, 2025
Enrollment
53 participants
Primary outcome

Incidence of Treatment-Emergent Adverse Events

Summary

The purpose of this study is to evaluate safety, tolerability, PK and immunogenicity of SV001
 compare to placebo in Chinese healthy adult volunteers.

ICD-10 classifications
Other interstitial pulmonary diseases with fibrosisCystic fibrosis with pulmonary manifestationsCystic fibrosisGraphite fibrosis (of lung)Pulmonary heart disease, unspecified
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06267183
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06267183 through Pure Global AI's free database. This Phase 1 trial is sponsored by Shanghai Synvida Biotechnology Co.,Ltd. and is currently Recruiting. The study focuses on Idiopathic Pulmonary Fibrosis. Target enrollment is 53 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.